CONGRESS ABSTRACT

Introduction: Cardiovascular (CV) comorbidities significantly contribute to the burden of OSAS disease and increase the complexity for management of this condition. The OSA-related rEDS (OSAREDS) study, planned and managed by AIMS (Accademia Italiana della Medicina del Sonno), collected data on cardiovascular comorbidities and their treatments. Aims and objectives: OSAREDS is a retrospective study, involving 7 sleep medicine centres dedicated to OSAS management, mainly aimed at assessing the prevalence of excessive daytime sleepiness (EDS) and residual EDS (rEDS) after OSAS treatment and at defining relationships between EDS and other symptoms and comorbidities. Methods: OSAS patients’ characteristics, symptoms, vital signs comorbidities, and treatments were collected retrospectively from medical records and analyzed. Results: 2663 patients (pts) included in the final analysis (males: 77.4%, mean age±SD: 55.7±9.4 yrs, BMI: 31.4±4.7 kg/m 2 ) had a baseline visit (V1) and 807 pts (males: 75.5%, mean age±SD: 56.6±9.0 yrs, BMI: 31.4±4.7 kg/m 2 ) had V1 and a control visit (V2) after 3-12 months (median 7.9 months) of CPAP treatment. In the whole cohort, anamnestic prevalence of hypertension, arrhythmias, coronary artery disease, congestive heart failure and stroke were, respectively: 56.6%, 7.5%, 8.4%, 2.9%, and 2.9%. According to blood pressure measurements, pts with borderline and high values were, respectively, 23.8% and 36.9%. CV diseases (CVD) were significantly (p<0.01) more frequent in pts without EDS (91%), than in sleepy pts. (82%). In the same population, the drugs indicated in CVD most often prescribed were Angiotensin II receptor blockers (20.2%), lipid lowering drugs (20.0%), antithrombotic agents (18.1%), b-blockers (17.7%), and ACE-inhibitors (16.7%). In pts with V1 and V2 visits anamnestic prevalence of hypertension, arrhythmias, coronary artery disease, congestive heart failure and stroke changed, respectively: from 60.6% to 52.0%, from 7.4% to 5.6%, from 10.9% to 11.2%, from 3.5% to 2.7%, and from 3.8% to 2.7%. Pts with borderline and high blood pressure values at V2 were, respectively, 10.4% and 12.4%. Conclusions: OSAREDS was the first study done on a large cohort of Italian OSAS pts which collected data on CVD. Its data confirmed, in these patients, the high prevalence both of CVD and of their treatments. Moreover, the trends of variables suggested a positive effect of CPAP treatment on some CVD.